HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Put On The Clock About NAC's Use As Dietary Ingredient After Amazon Ends Sales

CRN Files Citizen Petition After Letter To Agency Prompts No Action

Executive Summary

Trade group asked FDA six months ago to reverse position it revealed in July 2020 that products containing NAC cannot be marketed as dietary supplements. After Amazon in May reported pulling NAC supplements from its site, CRN decided to ask again.

You may also be interested in...



Consumer Health Products Claiming Treatments For Moles, COVID-19 Back On US FDA Warning Radar

Product sold on Amazon among topical remedies for mole and skin tag removal back on US regulatory radar. Recent warnings show violative COVID-19 claims haven’t disappeared and supplement GMP problems remain common.

NOW Health Kept NAC Flag Flying, US FDA Hoists Banner For Comment On Rulemaking Request

NOW Health continued marketing NAC supplements after FDA warned other firms, but some retailers opted out. FDA says rulemaking for NAC as lawful dietary ingredient is likely.

NAC Safety Docket Provides US FDA Cover From Acknowledging Preclusion Error, CRN Contends

“Single legal issue” is “whether the drug preclusion provision … properly precludes NAC from being marketed in dietary supplements,” CRN says in latest comment. Other stakeholders submit comments noting numerous studies showing NAC safety and decades of use in food products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel